Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor β correlates with the survival of breast cancer patients

Cancer Research

Volumn 66, Issue 5, 2006, Pages 2716-2724

  Savinov, Alexei Y ^a   Remacle, Albert G ^a   Golubkov, Vladislav S ^a   Krajewska, Maryla ^a   Kennedy, Susan ^b   Duffy, Michael J ^c   Rozanov, Dmitri V ^a   Krajewski, Stan ^a   Strongin, Alex Y ^a  

^a BURNHAM INSTITUTE   (United States)

^b ROYAL VICTORIA EYE AND EAR HOSPITAL   (Ireland)

^c ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; LIGAND; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 26; PROTEINASE; TUMOR MARKER; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; CARCINOMA IN SITU; CELL FUNCTION; COHORT ANALYSIS; COMPLEX FORMATION; CONTROLLED STUDY; DISEASE COURSE; GENE; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MMP 26 GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; TISSUE MICROARRAY; TRANSACTIVATION; TRANSCRIPTION REGULATION;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; ESTROGEN RECEPTOR BETA; HUMANS; MATRIX METALLOPROTEINASES; MATRIX METALLOPROTEINASES, SECRETED; NEOPLASM STAGING; SURVIVAL RATE;

EID: 33645046096     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3592     Document Type: Article

References (44)

1. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
2. Nagase H, Woessner JF, Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4.
3. Zhao YG, Xiao AZ, Newcomer RG, et al. Activation of pro-gelatinase B by endometase/matrilysin-2 promotes invasion of human prostate cancer cells. J Biol Chem 2003;278:15056-64.
4. Park HI, Turk BE, Gerkema FE, Cantley LC, Sang QX. Peptide substrate specificities and protein cleavage sites of human endometase/matrilysin-2/matrix metalloproteinase-26. J Biol Chem 2002;277:35168-75.
5. Marchenko ND, Marchenko GN, Strongin AY. Unconventional activation mechanisms of MMP-26, a human matrix metalloproteinase with a unique PHCGXXD cysteine-switch motif. J Biol Chem 2002;277:18967-72.
6. Li W, Savinov AY, Rozanov DV, et al. Matrix metalloproteinase-26 is associated with estrogen-dependent malignancies and targets α1-antitrypsin serpin. Cancer Res 2004;64:8657-65.
7. Yamamoto H, Vinitketkumnuen A, Adachi Y, et al. Association of matrilysin-2 (MMP-26) expression with tumor progression and activation of MMP-9 in esophageal squamous cell carcinoma. Carcinogenesis 2004;25:2353-60.
8. Marchenko ND, Marchenko GN, Weinreb RN, et al. β-Catenin regulates the gene of MMP-26, a novel metalloproteinase expressed both in carcinomas and normal epithelial cells. Int J Biochem Cell Biol 2004;36:942-56.
9. Goffin F, Munaut C, Frankenne F, et al. Expression pattern of metalloproteinases and tissue inhibitors of matrix-metalloproteinases in cycling human endometrium. Biol Reprod 2003;69:976-84.
10. Marchenko GN, Ratnikov BI, Rozanov DV, Godzik A, Deryugina EI, Strongin AY. Characterization of matrix metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin. Biochem J 2001;356:705-18.
11. Uria JA, Lopez-Otin C. Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity. Cancer Res 2000;60:4745-51.
12. de Coignac AB, Elson G, Delneste Y, et al. Cloning of MMP-26. A novel matrilysin-like proteinase. Eur J Biochem 2000;267:3323-9.
13. Park HI, Ni J, Gerkema FE, Liu D, Belozerov VE, Sang QX. Identification and characterization of human endometase (Matrix metalloproteinase-26) from endometrial tumor. J Biol Chem 2000;275:20540-4.
14. Isaka K, Nishi H, Nakai H, et al. Matrix metalloproteinase-26 is expressed in human endometrium but not in endometrial carcinoma. Cancer 2003;97:79-89.
15. Gustafsson JA. Estrogen receptor β-a new dimension in estrogen mechanism of action. J Endocrinol 1999;163:379-83.
16. Tong D, Schuster E, Seifert M, Czerwenka K, Leodolte S, Zeillinger R. Expression of estrogen receptor β isoforms in human breast cancer tissues and cell lines. Breast Cancer Res Treat 2002;71:249-55.
17. Pettersson K, Gustafsson JA. Role of estrogen receptor β in estrogen action. Annu Rev Physiol 2001;63:165-92.
18. Chegini N, Rhoton-Vlasak A, Williams RS. Expression of matrix metalloproteinase-26 and tissue inhibitor of matrix metalloproteinase-3 and -4 in endometrium throughout the normal menstrual cycle and alteration in users of levonorgestrel implants who experience irregular uterine bleeding. Fertil Steril 2003;80:564-70.
19. Pilka R, Whatling C, Domanski H, Hansson S, Eriksson P, Casslen B. Epithelial expression of matrix metalloproteinase-26 is elevated at mid-cycle in the human endometrium. Mol Hum Reprod 2003;9:271-7.
20. Li Q, Wang H, Zhao Y, Lin H, Sang QA, Zhu C. Identification and specific expression of matrix metalloproteinase-26 in rhesus monkey endometrium during early pregnancy. Mol Hum Reprod 2002;8:934-40.
21. Marchenko GN, Marchenko ND, Leng J, Strongin AY. Promoter characterization of the novel human matrix metalloproteinase-26 gene: regulation by the T-cell factor-4 implies specific expression of the gene in cancer cells of epithelial origin. Biochem J 2002;363:253-62.
22. Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 2003;22:177-203.
23. Ratnikov B, Deryugina E, Leng J, Marchenko G, Dembrow D, Strongin A. Determination of matrix metalloproteinase activity using biotinylated gelatin. Anal Biochem 2000;286:149-55.
24. Rozanov DV, Strongin AY. Membrane type-1 matrix metalloproteinase functions as a proprotein self-convertase. Expression of the latent zymogen in Pichia pastoris, autolytic activation, and the peptide sequence of the cleavage forms. J Biol Chem 2003;278:8257-60.
25. Rentrop M, Knapp B, Winter H, Schweizer J. Aminoalkylsilane-treated glass slides as support for in situ hybridization of keratin cDNAs to frozen tissue sections under varying fixation and pretreatment conditions. Histochem J 1986;18:271-6.
26. Krajewski S, Krajewska M, Turner BC, et al. Prognostic significance of apoptosis regulators in breast cancer. Endocr Relat Cancer 1999;6:29-40.
27. Mueller SO, Hall JM, Swope DL, Pedersen LC, Korach KS. Molecular determinants of the stereoselectivity of agonist activity of estrogen receptors (ER) α and β. J Biol Chem 2003;278:12255-62.
28. Bramlett KS, Burris TP. Target specificity of selective estrogen receptor modulators within human endometrial cancer cells. J Steroid Biochem Mol Biol 2003;86:27-34.
29. Robertson JA, Farnell Y, Lindahl LS, Ing NH. Estradiol up-regulates estrogen receptor messenger ribonucleic acid in endometrial carcinoma (Ishikawa) cells by stabilizing the message. J Mol Endocrinol 2002;29:125-35.
30. Cuezva JM, Krajewska M, de Heredia ML, et al. The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res 2002;62:6674-81.
31. Price JH, Goodacre A, Hahn K, et al. Advances in molecular labeling, high throughput imaging and machine intelligence portend powerful functional cellular biochemistry tools. J Cell Biochem Suppl 2002;39:194-210.
32. Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, et al. Estrogen receptor β (ERβ) level but not its ERβ ex variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res 2004;10:5769-76.
33. Fuqua SA, Schiff R, Parra I, et al. Expression of wild-type estrogen receptor β and variant isoforms in human breast cancer. Cancer Res 1999;59:5425-8.
34. Fuqua SA, Schiff R, Parra I, et al. Estrogen receptor β protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res 2003;63:2434-9.
35. Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SA. Low levels of estrogen receptor β protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res 2004;10:7490-9.
36. Park HI, Jin Y, Hurst DR, et al. The intermediate S1′ pocket of the endometase/matrilysin-2 active site revealed by enzyme inhibition kinetic studies, protein sequence analyses, and homology modeling. J Biol Chem 2003;278:51646-53.
37. Pilka R, Kudela M, Hansson S, Casslen B. [MMP-26 expression in endometrial explants treated with estradiol and progesterone]. Ceska Gynekol 2004;69:467-71.
38. Pilka R, Kudela M, Hansson S, Casslen B. [Novel matrix metalloproteinases in cycling endometrium]. Ceska Gynekol 2004;69:262-6.
39. Huang J, Li X, Maguire CA, Hilf R, Bambara RA, Muyan M. Binding of estrogen receptor β to estrogen response element in situ is independent of estradiol and impaired by its amino terminus. Mol Endocrinol 2005;19:2696-712.
40. Zhao YG, Xiao AZ, Park HI, et al. Endometase/matrilysin-2 in human breast ductal carcinoma in situ and its inhibition by tissue inhibitors of metalloproteinases-2 and -4: a putative role in the initiation of breast cancer invasion. Cancer Res 2004;64:590-8.
41. Ahokas K, Skoog T, Suomela S, et al. Matrilysin-2 (matrix metalloproteinase-26) is up-regulated in keratinocytes during wound repair and early skin carcinogenesis. J Invest Dermatol 2005;124:849-56.
42. Balbin M, Fueyo A, Tester AM, et al. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet 2003;35:252-7.
43. Jiang WG, Davies G, Martin TA, et al. Targeting matrilysin and its impact on tumor growth in vivo: the potential implications in breast cancer therapy. Clin Cancer Res 2005;11:6012-9.
44. Shiomi T, Okada Y. MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev 2003;22:145-52.